Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial (2021)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)00461-x

Publication URI: http://dx.doi.org/10.1016/s0140-6736(21)00461-x

Type: Journal Article/Review

Parent Publication: The Lancet

Issue: 10279